MW
Therapeutic Areas
Matinas Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MAT2203 | Invasive Candidiasis and Aspergillosis | Phase 2 |
| LNC Platform (siRNA/ASO delivery) | Inflammation (implied from research) | Preclinical |
Leadership Team at Matinas Biopharma
JD
Jerome D. Jabbour
Chief Executive Officer
KM
Keith Murphy
Independent Member, Board of Directors; Chair of Nominating and Governance Committee
EN
Edward Neugeboren
Independent Member, Board of Directors; Chair of Compensation Committee
ED
Evelyn D’An
Member, Board of Directors; Audit Committee Chair
DR
Dr. Robin L. Smith
Member, Board of Directors
NG
Natasha Giordano
Former Board Member